The non-randomized, open-label phase I study aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and pharmacokinetics of SST001 in healthy volunteers, patients with MSA and patients with PD.
Sign the informed consent form approved by IEC.
Male or female participants aged >18 years old.
Adequate organ functions.
Proper contraception methods.
Being pregnant or lactating.
History of other severe neurological disorders.
History of serious or uncontrolled medical condition.
Active HBV/HCV/HIV infection, etc.
Single group
SST001
DrugParticipants will undergo PET imaging after administration.
Incidence of Adverse Events
Number of participants with adverse events, serious adverse events, physical examination abnormalities, vital sign abnormalities, ECG abnormalities, clinical laboratory abnormalities, injection site reaction after drug injection.
Whole Body Effective Dose
Whole body effective dose calculated from whole-body PET scans of healthy participants.
Standardized Uptake Value Ratio (SUVR)
SUVR of SST001 in brain regions of interest.
Click on the lead sponsor to view all of their trials.
